In the BioHarmony Drug Report Database

"Preview" Icon

Semaglutide

Ozempic, Rybelsus, Wegovy (semaglutide) is a protein pharmaceutical. Semaglutide was first approved as Ozempic on 2017-12-05. It has been approved in Europe to treat diabetes mellitus and type 2 diabetes mellitus. The pharmaceutical is active against glucagon-like peptide 1 receptor. Ozempic’s patents are valid until 2038-08-24 (FDA).

 

Trade Name

 

Ozempic, Rybelsus
 

Common Name

 

semaglutide
 

ChEMBL ID

 

CHEMBL2108724
 

Indication

 

diabetes mellitus, type 2 diabetes mellitus
 

Drug Class

 

Peptides: GLP peptide analogs

Image (chem structure or protein)

Semaglutide structure rendering